Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 9/20 | 0.56 |
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5168032 | 1.00 | CA1 (0.58) | CA1CA2CA4CA7MAPT | |
| SCHEMBL5168035 | 1.00 | CA1 (0.58) | CA1CA2CA4CA7MAPT | |
| SCHEMBL18660291 | 0.88 | CA1 (0.59) | CA1CA2CA4CA7MAPT | |
| SCHEMBL18660293 | 0.88 | CA1 (0.59) | CA1CA2CA4CA7MAPT | |
| SCHEMBL1919676 | 0.87 | CA1 (0.58) | CA1CA2CA4CA7MAPT | |
| SCHEMBL6501806 | 0.87 | CA1 (0.58) | CA1CA2CA4CA7MAPT | |
| SCHEMBL1919310 | 0.87 | CA1 (0.58) | CA1CA2CA4CA7MAPT | |
| SCHEMBL518527 | 0.83 | MAPT (0.55) | CA1CA2CA4CA7MAPT | |
| SCHEMBL8588938 | 0.83 | HPGD (0.50) | CA1CA2CA4CA7MAPT | |
| SCHEMBL8588896 | 0.83 | HPGD (0.50) | CA1CA2CA4CA7MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938272-B2 | Hydrazine compound as blood coagulation factor Xa inhibitor | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2018-04-10 | — | — | US | disclosed |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | NORTH CHINA PHARMACEUTICAL COMPANY., LTD. (CN) | 2017-06-01 | — | — | US | disclosed |
| US-7579472-B2 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| US-7435821-B2 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080009626-A1 | Reacting a 3-leaving group-1-(p-leaving group-phenyl)tetrahydro-2-pyridone with 2-hydroxypyridine and reacting the product with an alpha-oxoacetaldehyde phenylhydrazone to form 1-phenyl-3-carbonyl-6-(p-(2-pyridon-1-yl)phenyl-4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives; bases; aprotic solvents | MUDRYK BOGUSLAW M | 2008-01-10 | — | — | US | disclosed |
| US-20070282106-A1 | EFFICIENT SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-c]PYRID-2-ONES | MUDRYK BOGUSLAW M | 2007-12-06 | — | — | US | disclosed |
| US-20070282106-A1 | EFFICIENT SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-c]PYRID-2-ONES | MUDRYK BOGUSLAW M | 2007-12-06 | — | — | US | disclosed |
| US-7304157-B2 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304157-B2 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060069119-A1 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282106-A1 | EFFICIENT SYNTHESIS OF 4,5-DIHYDRO-PYRAZOLO[3,4-c]PYRID-2-ONES | F2, TFPI, PDXK | CA1 3083/4885CA2 2470/4885CA4 992/4885 |
| US-20170152259-A1 | HYDRAZINE COMPOUND AS BLOOD COAGULATION FACTOR Xa INHIBITOR | F12, F10, F11 | CA1 240/4885CA2 323/4885CA4 269/4885 |
| US-20060069119-A1 | Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones | F2, TFPI, PDXK | CA1 3083/4885CA2 2470/4885CA4 992/4885 |
| US-20080009626-A1 | Reacting a 3-leaving group-1-(p-leaving group-phenyl)tetrahydro-2-pyridone with 2-hydroxypyridine and reacting the product with an alpha-oxoacetaldehyde phenylhydrazone to form 1-phenyl-3-carbonyl-6-(p-(2-pyridon-1-yl)phenyl-4,5-dihydro-pyrazolo[3,4-c]pyrid-2-one derivatives; bases; aprotic solvents | PDXK, PLPBP, PNPO | CA1 1137/4885CA2 1227/4885CA4 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.